ArriVent BioPharma (NASDAQ: AVBP) recently received a number of ratings updates from brokerages and research firms:
- 11/16/2026 – ArriVent BioPharma had its price target lowered by Guggenheim from $30.00 to $28.00. They now have a “buy” rating on the stock.
- 11/14/2026 – ArriVent BioPharma was upgraded by Wall Street Zen from “sell” to “hold”.
- 11/12/2026 – ArriVent BioPharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 11/10/2026 – ArriVent BioPharma had its price target raised by Truist Financial from $21.00 to $24.00. They now have a “buy” rating on the stock.
- 10/27/2026 – ArriVent BioPharma had its price target raised by Guggenheim from $18.00 to $30.00. They now have a “buy” rating on the stock.
- 10/26/2026 – ArriVent BioPharma was given a new $21.00 price target by Truist Financial.
- 10/26/2026 – ArriVent BioPharma had its “outperform” rating reaffirmed by Oppenheimer. They now have a $25.00 price target on the stock.
- 10/20/2026 – ArriVent BioPharma had its price target lowered by B. Riley Financial from $45.00 to $29.00. They now have a “buy” rating on the stock.
- 10/18/2026 – ArriVent BioPharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 10/16/2026 – ArriVent BioPharma had its “buy” rating reaffirmed by BTIG Research. They now have a $29.00 price target on the stock.
- 10/15/2026 – ArriVent BioPharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/10/2026 – ArriVent BioPharma was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 10/8/2026 – ArriVent BioPharma had its price target lowered by HC Wainwright from $47.00 to $27.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by Guggenheim from $45.00 to $18.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by BTIG Research from $42.00 to $29.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by Citigroup from $40.00 to $20.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by JonesTrading from $45.00 to $22.00. They now have a “buy” rating on the stock.
- 10/6/2026 – ArriVent BioPharma had its price target lowered by Truist Financial from $45.00 to $18.00. They now have a “buy” rating on the stock.
- 10/6/2026 – ArriVent BioPharma was given a new $18.00 price target by Jefferies Financial Group.
- 9/22/2026 – ArriVent BioPharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
ArriVent BioPharma Price Performance
Shares of NASDAQ:AVBP opened at $10.69 on Wednesday. The firm has a fifty day moving average price of $20.58 and a two-hundred day moving average price of $26.29. ArriVent BioPharma, Inc. has a one year low of $10.49 and a one year high of $35.83. The company has a market cap of $552.89 million, a price-to-earnings ratio of -2.97 and a beta of 1.66.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts expect that ArriVent BioPharma, Inc. will post -3.81 EPS for the current fiscal year.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.
Read More
- Five stocks we like better than ArriVent BioPharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for ArriVent BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.
